Generic Medicine Info
Patient w/ TB or other severe infections (e.g. sepsis, abscesses, opportunistic infections), moderate or severe heart failure (NYHA class III or IV).
Special Precautions
Patient w/ mild heart failure (NYHA class I or II), history of blood dyscrasias, chronic or recurrent infection. Childn. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for signs and/or symptoms of infection, hypersensitivity reaction, lupus-like syndrome, heart failure, malignancy. Monitor vital signs every 2-10 min if reaction is noted during infusion. Perform hepatitis B virus screening prior to and hepatitis B virus carriers during and several mth after therapy; CBC w/ differential, LFTs.
Adverse Reactions
Chills, fever, dyspnoea, chest pain, HTN or hypotension, urticaria, pruritus, nausea, vomiting, diarrhoea, abdominal pain, fatigue, dizziness, headache, back pain, hypersensitivity, upper resp tract infection, UTI, new-onset or exacerbation of heart failure; delayed reactions: myalgia, fever, arthralgia, rash. Rarely, lupus-like syndrome, sarcoidosis or sarcoid-like reaction, anaphylactic reactions, exacerbation of demyelinating disorders (e.g. multiple sclerosis, optic neuritis).
Potentially Fatal: Hepatitis B reactivation in chronic carriers. Rarely, serious opportunistic infections, bacterial sepsis, invasive fungal infections, pneumonia, onset or reactivation of TB, severe hepatic reactions (e.g. acute liver failure, jaundice, cholestasis, hepatitis, blood dyscrasias (e.g. leucopenia, thrombocytopenia, pancytopenia, aplastic anaemia), interstitial lung disease (e.g. pneumonitis, pulmonary fibrosis), lymphoma and other malignancies (e.g. hepatosplenic T-cell lymphoma, leukaemia).
Drug Interactions
Increased risk of serious infection and neutropenia w/ anakinra or abatacept. Risk of clinical infections, including disseminated infections w/ concurrent admin of live vaccines.
ATC Classification
L04AB02 - infliximab ; Belongs to the class of tumor necrosis factor alpha (TNF-a) inhibitors. Used as immunosuppressants.
Disclaimer: This information is independently developed by CIMS based on infliximab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in